There are relatively few targeted drugs for esophageal cancer, and the following are commonly used clinically: i. Gefitinib, which is mainly a small molecule surface growth factor and receptor complex kinase inhibitor, is mostly used for patients with advanced stage of esophageal cancer, and its effect is more ideal. Second, cetuximab can also be used, mainly by blocking the combination of EGFR and ligand, to inhibit the continued differentiation and angiogenesis of tumor cells, which can effectively carry out to healing inhibition for esophageal cancer patients. After clinical practice, it has been shown that these targeted drugs can be combined with radiotherapy and chemotherapy, which may produce more desirable effects on progressive esophageal cancer and also produce less side effects. Thirdly, there are also bevacizumab, which have been clinically proven to be more effective in advanced esophageal cancer.